Top entities: Zelluna ASA, Inven2 AS, Norway — Norwegian krone, Norway — Norwegian Register of Business Enterprises, European Union — Euro.

What category does this event fall under?

Business — classified as share issuance.

What is the sentiment of coverage?

Aggregate sentiment score: 10 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

What were the key actions taken?

Zelluna ASA issued shares Inven2 AS · Zelluna ASA completed private placement

Is this event still developing?

This is an active story, last updated Aug 10, 2026. Coverage continues to evolve.

Business share issuance

Zelluna issues shares to Inven2

Q: When did this event occur?

First reported Aug 04, 2026; last updated Aug 10, 2026.

Q: What is the market impact?

General. The issuance is a routine corporate action that settles a debt obligation and increases Zelluna's share capital, with minimal direct market impact.

Analysis based on 7 articles · First reported Aug 04, 2026 · Last updated Aug 10, 2026

Sentiment

Attention

Articles

Market Impact

General

Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

Market Impact

The issuance is a routine corporate action that settles a debt obligation and increases Zelluna's share capital, with minimal direct market impact. It signals progress in Zelluna's clinical development, which may be viewed slightly positively by investors.

Biotechnology

Event Summary

Zelluna ASA, a biotech company developing TCR-NK cell therapies for solid cancers, issued 446,752 new shares to Inven2 AS at a subscription price of NOK 19.7752 per share, increasing its share capital from NOK 29,413,759 to NOK 29,860,511. The issuance was made to settle amounts owed to Inven2 under an option and license agreement with Zelluna's wholly owned subsidiary Zelluna ASA, triggered by the dosing of the first patient in the first clinical trial for a licensed product. The share capital increase was registered with the Norway — Norwegian Register of Business Enterprises on 10 August 2026.

Key Actions

80 Zelluna ASA issued shares Inven2 AS

70 Zelluna ASA completed private placement

Entities Involved

priv

Zelluna ASA

Zelluna issued new shares to settle a debt, increasing its share capital. This reflects progress in its clinical program and maintains its relationship with Inven2.

Importance 100.0 Sentiment 10.0

priv

Inven2 AS

Inven2 received 446,752 new shares in Zelluna as settlement for amounts owed under an option and license agreement, becoming a shareholder.

Importance 80.0 Sentiment 10.0

curr

Norway — Norwegian krone

The Norway — Norwegian krone is the currency in which the share capital increase and subscription price are denominated.

Importance 30.0 Sentiment 0.0

govactor

Norway — Norwegian Register of Business Enterprises

The register processed the registration of the share capital increase, a routine administrative step.

Importance 20.0 Sentiment 0.0

curr

European Union — Euro

The European Union — Euro is used in the settlement amount owed to Inven2, but the event does not affect the currency's value.

Importance 20.0 Sentiment 0.0

exch

Oslo Stock Exchange

Zelluna is listed on the Oslo Stock Exchange, where the new shares will be traded, but the event has minimal impact on the exchange itself.

Importance 20.0 Sentiment 0.0

per

Namir Hassan

As CEO, Namir Hassan is a contact person for the announcement but has no direct role in the event.

Importance 10.0 Sentiment 0.0

per

Geir Christian Melen

As CFO, Geir Christian Melen is a contact person for the announcement but has no direct role in the event.

Importance 10.0 Sentiment 0.0

ERGEN INTELLIGENCE

Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard